Payment overview · 2025
General Payments
$76.68
5 reported records · 4 companies
Healthcare provider profile · identity verified
Thomas Alvis Thacker, DO
Allopathic & Osteopathic Physicians|Family Medicine · ALBANY, KY · NPI 1922251123
Verified facts
What the public records show
CMS Open Payments records show Thomas Alvis Thacker, DO received $76.68 in general payments during 2025 across 5 reported records.
Amgen Inc. accounted for 38.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.58 | 38.6% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.85 | 23.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.47 | 20.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $13.78 | 18.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $76.68 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $29.58 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.58 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.85 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.47 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.47 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $13.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 428 | 112 |
| Gabapentin | Gabapentin | 295 | 75 |
| Levothyroxine Sodium | Levothyroxine Sodium | 294 | 61 |
| Amlodipine Besylate | Amlodipine Besylate | 283 | 94 |
| Lisinopril | Lisinopril | 266 | 77 |
| Pantoprazole Sodium | Pantoprazole Sodium | 233 | 71 |
| Sertraline Hcl | Sertraline Hcl | 219 | 48 |
| Furosemide | Furosemide | 206 | 57 |
| Eliquis | Apixaban | 192 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 181 | 48 |
| Metformin Hcl | Metformin Hcl | 176 | 40 |
| Trazodone Hcl | Trazodone Hcl | 173 | 41 |
| Losartan Potassium | Losartan Potassium | 147 | 44 |
| Potassium Chloride | Potassium Chloride | 146 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 139 | 37 |
| Omeprazole | Omeprazole | 132 | 45 |
| Donepezil Hcl | Donepezil Hcl | 123 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 117 | 36 |
| Tizanidine Hcl | Tizanidine Hcl | 111 | 41 |
| Doxycycline Hyclate | Doxycycline Hyclate | 106 | 86 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 99 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 98 | 37 |
| Ondansetron Odt | Ondansetron | 98 | 59 |
| Memantine Hcl | Memantine Hcl | 93 | 15 |
| Prednisone | Prednisone | 93 | 68 |
| Clopidogrel | Clopidogrel Bisulfate | 91 | 30 |
| Meloxicam | Meloxicam | 91 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 88 | 30 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 75 | 55 |
| Clonazepam | Clonazepam | 75 | 14 |
| Montelukast Sodium | Montelukast Sodium | 74 | 37 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 73 | 18 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 72 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 72 | 33 |
| Hydralazine Hcl | Hydralazine Hcl | 71 | 27 |
| Carvedilol | Carvedilol | 69 | 25 |
| Cefdinir | Cefdinir | 67 | 60 |
| Lorazepam | Lorazepam | 63 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 62 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 61 | 17 |
| Allopurinol | Allopurinol | 60 | 13 |
| Tramadol Hcl | Tramadol Hcl | 60 | 30 |
| Buspirone Hcl | Buspirone Hcl | 58 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 58 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 56 | 19 |
| Famotidine | Famotidine | 55 | 14 |
| Levofloxacin | Levofloxacin | 54 | 46 |
| Rybelsus | Semaglutide | 52 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 51 | 14 |
| Fluconazole | Fluconazole | 50 | 34 |
| Diclofenac Sodium | Diclofenac Sodium | 49 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 49 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 15 |
| Divalproex Sodium | Divalproex Sodium | 48 | 11 |
| Olanzapine | Olanzapine | 48 | 12 |
| Ozempic | Semaglutide | 48 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 47 | 32 |
| Mirtazapine | Mirtazapine | 47 | 18 |
| Promethazine Hcl | Promethazine Hcl | 45 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | 11 |
| Clonidine Hcl | Clonidine Hcl | 42 | 22 |
| Finasteride | Finasteride | 42 | suppressed |
| Glimepiride | Glimepiride | 42 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 38 | 11 |
| Celecoxib | Celecoxib | 37 | suppressed |
| Levetiracetam | Levetiracetam | 37 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 37 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | suppressed |
| Risperidone | Risperidone | 35 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 24 |
| Baclofen | Baclofen | 34 | suppressed |
| Glipizide | Glipizide | 34 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 34 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 29 |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 33 | suppressed |
| Spironolactone | Spironolactone | 33 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | 12 |
| Azithromycin | Azithromycin | 31 | 25 |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Simvastatin | Simvastatin | 30 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | 12 |
| Carbamazepine | Carbamazepine | 29 | suppressed |
| Ketoconazole | Ketoconazole | 29 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 29 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 17 |
| Metoclopramide Hcl | Metoclopramide Hcl | 27 | suppressed |
| Nystatin | Nystatin | 27 | 18 |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Klayesta | Nystatin | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 25 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 18 |
| Atenolol | Atenolol | 24 | suppressed |
| Alprazolam | Alprazolam | 23 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 23 | suppressed |
| Jardiance | Empagliflozin | 23 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 22 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 20 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Gemfibrozil | Gemfibrozil | 19 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 19 | suppressed |
| Phenobarbital | Phenobarbital | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | suppressed |
| Budesonide | Budesonide | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Haloperidol | Haloperidol | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 14 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Nabumetone | Nabumetone | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $76.68 · 5 records | Amgen Inc. | BREZTRI, CAPLYTA, OTEZLA, QULIPTA, REPATHA, UBRELVY | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error